Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Drilon on NTRK Rearrangement in Lung Cancer

March 3rd 2017

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses NTRK rearrangement in patients with lung cancer.

EC Approves Alectinib for ALK+ NSCLC

February 25th 2017

The European Commission has approved alectinib (Alecensa) as a treatment for patients with metastatic ALK-positive non–small cell lung cancer following progression on crizotinib (Xalkori).

CHMP Recommends Dabrafenib/Trametinib Combo in BRAF+ NSCLC

February 24th 2017

The EMA’s Committee for Medicinal Products for Human Use has recommended approval of the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) as a treatment for patients with advanced or metastatic BRAF V600E-mutant non-small cell lung cancer.

Pembrolizumab Long-Term Survival Rate Could Reach 25% in NSCLC

February 24th 2017

Treatment with pembrolizumab could elicit long-term survival rates of 21% to 25% for previously-treated patients with PD-L1–positive non–small cell lung cancer compared with 3% to 4% for docetaxel.

FDA Grants Ceritinib Priority Review in Frontline ALK+ NSCLC

February 24th 2017

The FDA has granted a priority review to ceritinib as a first-line treatment for patients with ALK-positive, metastatic non–small cell lung cancer.

Final Thoughts on Squamous NSCLC Research

February 21st 2017

EGFR-Targeted Therapy for Squamous NCSLC

February 21st 2017

Further Sequencing in Squamous NSCLC

February 21st 2017

Choosing Second-Line Therapy for Squamous NSCLC

February 21st 2017

Maintenance Therapy for Squamous NSCLC

February 21st 2017

Chemotherapy for Newly Diagnosed Squamous NSCLC

February 21st 2017

Promising Immunotherapy Trials in Squamous NSCLC

February 21st 2017

Pseudoprogression on Immunotherapy in Squamous NSCLC

February 21st 2017

Toxicities Associated with Anti-PD-1 Immunotherapy

February 21st 2017

Pembrolizumab in Newly Diagnosed Squamous NSCLC

February 21st 2017

PD-L1 Testing in Squamous NSCLC

February 21st 2017

EGFR & ALK/ROS1 Testing in Squamous NSCLC

February 21st 2017

What to Do After Progression on Immunotherapy and for Non-Driver NSCLC

February 20th 2017

New Data for Checkpoint Inhibitors in NSCLC

February 20th 2017

PD-L1 Testing for NSCLC

February 20th 2017